We are live on
!
Find out more
KE
KLP Enterprises Portfolio holdings
AUM
$1.97M
This Fund
S&P 500
This Quarter
Est. Return
-12.38%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$24.3M
AUM Growth
–
Cap. Flow
+$26M
Cap. Flow
% of AUM
107.13%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
1
New
1
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celldex Therapeutics
CLDX
|
+$26M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Celldex Therapeutics
CLDX
$2.76B
| $24.3M | 100% |
+457,667
| New | +$26M |
|
Similar funds
FFG
GFT
SCU
NPAM
ZCM
CM
6C
CCM
KLP Enterprises's Q4 2016 Portfolio in Review
Q4 2016 is the first quarter with a 13F filing on record for KLP Enterprises, which disclosed 1 position worth $24.3M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Celldex Therapeutics: 457,667 shares worth $24.3M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- KLP Enterprises's largest Q4 2016 buy was Celldex Therapeutics: 457,667 shares worth $24.3M.
- KLP Enterprises's ten largest holdings make up 100% of its $24.3M portfolio in Q4 2016.
- KLP Enterprises disclosed 1 position in Q4 2016, its first 13F filing on record.
Based on KLP Enterprises's 13F filing for Q4 2016, filed 10 Feb 2017.